Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Johnson & Johnson (J&J) has reported data from the Phase III ICONIC-LEAD trial’s subgroup analysis evaluating icotrokinra in ...

Icotrokinra is efficacious and safe for treating moderate to severe plaque psoriasis among adolescents and adults when compared with placebo.

New results from a subgroup analysis of the ICONIC-LEAD study showed icotrokinra was effective and safe for the treatment of moderate to severe plaque psoriasis in adolescents, according to a press ...

Two phase 2 trials with different selective TYK2 inhibitors produce high rates of efficacy in moderate to severe plaque ...

Deucravacitinib has been observed as a safe and efficacious treatment for adults with moderate to severe plaque psoriasis for up to 4 years.

Icotrokinra achieved 75% complete skin clearance in adolescents with moderate to severe plaque psoriasis by week 24, indicating significant efficacy. The ICONIC-LEAD trial is the first to evaluate ...

(RTTNews) - Johnson & Johnson (JNJ) announced new icotrokinra (JNJ-2113) data from its Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis (PsO ...